Charles Hollen
Hematology & Oncology · Oklahoma City, OKNPI 1205855723
Payments from drug & device makers
Across 512 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Johnson & Johnson$940
- Pfizer$766
- Seagen Inc.$726
- AstraZeneca$483
- Lilly USA, LLC$393
- plus $5K from 44 others
What the payments were for
- Food & beverage$8,02877%
- Education$1,32813%
- Other$1,01510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,371 in reported general payments places this provider in the 60th percentile of 118 hematology & oncology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 18 | $514 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Oklahoma City
- Adam AschOklahoma City$2M
- Adanma Anji Ayanambakkam AttanathiOklahoma City$1.9M
- Hassan HatoumOklahoma City$1.4M
- Abdul Rafeh NaqashOklahoma City$1.1M
- Sami IbrahimiOklahoma City$1M
- Carrie YuenOklahoma City$564K
- David LamOklahoma City$445K
- Romeo MandanasOklahoma City$419K
- Carla KurkjianOklahoma City$310K
- Sonia VargheseOklahoma City$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.